2012 Current Cancer Dedicated to bringing the latest news and information on cancer diagnosis, treatment and prevention.


Over 1000 Clinical Cases Evaluated Using IQQA®-Liver In Supporting Multidisciplinary Liver Imaging Evaluations

Advertiment

EDDA Technology announced that the number of clinical cases evaluated for pre- and post- operative assessment using IQQA®-Liver in hospitals has exceeded 1000 examinations, since the first commercial system installation in Q2 2009. EDDA’s IQQA®-Liver, now marketed worldwide, is a comprehensive workflow solution supporting modern multidisciplinary liver imaging evaluation and management.

Primary liver cancer represents one of the most common malignancies in the world and accounts for almost 1.25 million deaths annually. In the US, liver disease is among the ten major causes of death. The management of hepatic tumors presents a challenging problem. Advanced preoperative imaging assessment is paramount in determining appropriate treatment, and requires the participation of a multidisciplinary team of surgeons, oncologists, hepatologists, and interventional radiologists specializing in liver malignancy.

IQQA®-Liver is designed to cope with such a challenge. It provides an innovative toolset for real-time interactive assessment and volumetric quantification of liver, liver lobes, hepatics lesions and vessels. With the intuitive and easy-to-use tools, physicians may in real-time perform virtual simulation of resection, lobular/segmental/vascular manipulation and quantification to achieve desired planning result typically within minutes.

EDDA’s proprietary IT technology allows enterprise-wide deployment of IQQA®-Liver via web so as to quick share data and results anywhere anytime among the multidisciplinary liver team.

IQQA®-Liver has clearance by the FDA, China SFDA, Taiwan DOH, and carries the CE mark. It is currently in use at numerous prestigious liver transplantation/surgery/interventional centers worldwide, including University of Colorado Hospitals Denver, Shanghai Zhongshan Hospital, Shanghai Ruijin Hospital, Tianjin First Center Hospital, Beijing You’an Hospital, Nanjing Gulou Hospital and etc.

In one study, University of Colorado Hospital Denver used IQQA®-Liver to retrospectively evaluate the entire living liver donor (LLD) candidate studies rejected in a 2 year period, and found that about 48% that were previously rejected due to anatomic abnormalities by conventional CT visualization could have favorable anatomy for LLD. According to Dr. Igal Kam, Chief of Transplantation, and Dr. Paul Russ, Professor of Radiology, “IQQA®-Liver allows for better understanding of surgical anatomy and surgical planning in the preoperative evaluation. This will have positive outcome on available livers and LLD selection.” Results will be presented at the XXIII International Congress of the Transplantation Society in Vancouver. EDDA will exhibit IQQA®-Liver at this congress (booth #38).

Source: EDDA Technology, Inc

Leave a Reply

Suggested Posts

Joint Clinical Practice Guidelines On Hepatocellular Carcinoma Management To Be Published By EASL-EORTC EDDA Tech ology a ou ced that the umber of cli ical cases evaluated for pre- a d post- operative assessme t usi g IQQA®-Liver i hospitals has exceeded 1000 exami atio s, si ce the first commercial system i stallatio i Q2 2009. EDDA’s IQQA®-Liver, ow marketed worldwide, is a comprehe sive workflow solutio supporti g moder multidiscipli ary liver imagi g evaluatio a d ma ageme t. Primary liver ca cer represe ts [...]. Posted August 13th, 2010 | 9:41 am
New Evidence Strengthens Link Between Opioids And Cancer Growth EDDA Tech ology a ou ced that the umber of cli ical cases evaluated for pre- a d post- operative assessme t usi g IQQA®-Liver i hospitals has exceeded 1000 exami atio s, si ce the first commercial system i stallatio i Q2 2009. EDDA’s IQQA®-Liver, ow marketed worldwide, is a comprehe sive workflow solutio supporti g moder multidiscipli ary liver imagi g evaluatio a d ma ageme t. Primary liver ca cer represe ts [...]. Posted August 13th, 2010 | 9:41 am
Two Cancer-Promoting Pathways Linked In Esophageal Cancer EDDA Tech ology a ou ced that the umber of cli ical cases evaluated for pre- a d post- operative assessme t usi g IQQA®-Liver i hospitals has exceeded 1000 exami atio s, si ce the first commercial system i stallatio i Q2 2009. EDDA’s IQQA®-Liver, ow marketed worldwide, is a comprehe sive workflow solutio supporti g moder multidiscipli ary liver imagi g evaluatio a d ma ageme t. Primary liver ca cer represe ts [...]. Posted August 13th, 2010 | 9:41 am
Using Molecular Analysis To Identify Specific Cancers EDDA Tech ology a ou ced that the umber of cli ical cases evaluated for pre- a d post- operative assessme t usi g IQQA®-Liver i hospitals has exceeded 1000 exami atio s, si ce the first commercial system i stallatio i Q2 2009. EDDA’s IQQA®-Liver, ow marketed worldwide, is a comprehe sive workflow solutio supporti g moder multidiscipli ary liver imagi g evaluatio a d ma ageme t. Primary liver ca cer represe ts [...]. Posted August 13th, 2010 | 9:41 am
Establishing National Standards For Cancer Survivorship Care EDDA Tech ology a ou ced that the umber of cli ical cases evaluated for pre- a d post- operative assessme t usi g IQQA®-Liver i hospitals has exceeded 1000 exami atio s, si ce the first commercial system i stallatio i Q2 2009. EDDA’s IQQA®-Liver, ow marketed worldwide, is a comprehe sive workflow solutio supporti g moder multidiscipli ary liver imagi g evaluatio a d ma ageme t. Primary liver ca cer represe ts [...]. Posted August 13th, 2010 | 9:41 am